t
Tern Plc announced on 25 November 2025 that the maturity dates of its approximately £0.3 million convertible loan notes (CLNs) in Talking Medicines Limited have been extended. A proportion of these CLNs were due to mature on 30 November 2025, and all of Tern's CLNs in Talking Medicines have now been extended to 21 November 2029, with their terms and conditions equalised.
| Date | 25 Nov 2025 |
| Time | 07:00:21 |
| Category | Miscellaneous |
| ID | 8132I |
25 November 2025
Tern Plc
("Tern" or the "Company")
Talking Medicines Convertible Loan Note Modifications
Tern Plc (AIM:TERN), the investment company specialising in supporting high growth, early-stage, disruptive Internet of Things ("IoT") technology businesses, announces that the maturity dates of the approximately £0.3 million of convertible loan notes ("CLNs") that the Company holds in Talking Medicines Limited ("Talking Medicines") have been extended, with all of Tern's CLNs in Talking Medicines being extended to 21 November 2029.
A proportion of the CLNs were due to mature on 30 November 2025 and the maturity dates of all of Talking Medicines' outstanding CLNs have now been extended, together with the terms and conditions of the various tranches of Talking Medicines CLNs being equalised, to reflect the CLN terms described in Tern's announcement of 1 February 2024. The Tern directors believe that this will place Tern in a more advantageous negotiating position with regard to any exit from Tern's holding in Talking Medicines.
Enquiries
|
Tern Plc Jane McCracken (Interim Non-Executive Chair) |
via IFC Advisory |
|
Allenby Capital Limited (Nominated Adviser and Broker) Alex Brearley / Ashur Joseph (Corporate Finance) Kelly Gardiner (Sales and Corporate Broking) |
Tel: 0203 328 5656 |
|
IFC Advisory (Financial PR and IR) Tim Metcalfe Graham Herring Florence Staton |
Tel: 0203 934 6630 |